Stephan Gasser

Title: The Innovations of Stephan Gasser

Introduction

Stephan Gasser, an accomplished inventor based in Schlieren, Switzerland, has made significant contributions to the field of biomedicine. With a focus on developing innovative therapeutic agents, he holds two notable patents that showcase his expertise in antigen binding molecules. His work aims to address critical medical challenges through groundbreaking scientific discoveries.

Latest Patents

Stephan's latest patents include:

1. **Agonistic CD28 antigen binding molecules targeting Her2** - This invention pertains to Her2-targeted bispecific agonistic CD28 antigen binding molecules, characterized by a monovalent binding to CD28. The patent outlines methods for producing these antibodies, pharmaceutical compositions that include them, and various methods for their application in therapeutic settings.

2. **Tumor-targeted agonistic CD28 antigen binding molecules** - This patent also focuses on bispecific agonistic antigen binding molecules, emphasizing monovalent binding to CD28. Similar to his previous patent, it details methods for production, pharmaceutical compositions containing these antibodies, and potential methods of use, which could play a vital role in treating tumors.

Career Highlights

Stephan Gasser is associated with Hoffmann-La Roche Inc., a leading global healthcare company. His work there emphasizes the integration of innovative research with practical applications to improve patient care and treatment options. His contributions have positioned him as a notable figure in the realm of therapeutic development.

Collaborations

Throughout his career, Stephan has collaborated with esteemed colleagues, including Guy Georges and Thomas U Hofer. These collaborations exemplify teamwork and innovation in research, allowing for a synergistic approach to developing advanced therapeutic agents.

Conclusion

In conclusion, Stephan Gasser's inventive spirit and dedication to research have led to significant contributions in biomedical innovation. With two valuable patents to his name, his ongoing work at Hoffmann-La Roche Inc. continues to impact the scientific community positively. His contributions hold promise for improved therapies that target Her2 and tumors, reflecting a commitment to advancing healthcare through innovation.